Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2018

View Archived Issues

Natural and engineered L. lactis as a novel probiotic strategy for cholera protection and diagnosis

Carbetocin is noninferior to oxytocin to prevent postpartum hemorrhage with better heat stability

Encochleated atovaquone formulation evaluated in mouse model of pneumocystis pneumonia

Phase II data presented from ORIENT-1 study of sintilimab in patients with Hodgkin's lymphoma

Phase I/II data for veliparib as add-on therapy for the treatment of HNSCC

Clinical trial authorization granted in U.K. for phase I study of FOR-6219

BMS-986253 well tolerated in phase I study in patients with metastatic or unresectable solid tumors

RND efflux pump inhibitor MBX-4191 developed at Microbiotix for Gram-negative Enterobacteriaceae

Conserved haplotype in SGLT1 is linked with lower risk of dietary hyperglycemia

In vivo evaluation of albumin-binding PSMA analogue [177Lu]HTK-01169 in LNCaP tumor xenograft model

New Era Pharma presents Sgk1 and/or Sgk2 inhibitors

Introducing BioWorld Science: supporting R&D decisions through drug discovery and preclinical news

Celtaxsys divulges new LTA-4 hydrolase inhibitors

Sanofi and Lead Pharma Holding patent RORC modulators

Shenzhen Targetrx Biotechnology presents EGFR mutant inhibitors

Sumitomo Dainippon seeks Japanese approval for thiotepa as pre-HSCT conditioning treatment

Roche initiates phase I study of RO-7172508 in CEA-positive solid tumors

TLR7 agonists presented by Apros Therapeutics

Mitsubishi Tanabe studies MT-7117 in phase II for erythropoietic protoporphyria

Antibe reports secondary endpoint data from phase IIb GI safety study of ATB-346

Immutep submits IND to begin phase II study of eftilagimod with Keytruda

Phase II study of pacritinib in myelofibrosis cleared to continue by IDMC

IDMC clears phase III study of Tedopi in NSCLC to continue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...